Glomerulonephritis - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 124
Inquire Before Buying

Global Markets Direct's, ‘Glomerulonephritis - Pipeline Review, H2 2016', provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis

  • The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects

  • The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Glomerulonephritis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Glomerulonephritis - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Glomerulonephritis Overview 9
Therapeutics Development 10
Pipeline Products for Glomerulonephritis - Overview 10
Pipeline Products for Glomerulonephritis - Comparative Analysis 11
Glomerulonephritis - Therapeutics under Development by Companies 12
Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes 15
Glomerulonephritis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Glomerulonephritis - Products under Development by Companies 19
Glomerulonephritis - Products under Investigation by Universities/Institutes 21
Glomerulonephritis - Companies Involved in Therapeutics Development 22
Achillion Pharmaceuticals, Inc. 22
Alexion Pharmaceuticals Inc 23
Amyndas Pharmaceuticals LLC 24
Anthera Pharmaceuticals Inc 25
Avexxin AS 26
Biogen Inc 27
Complexa, Inc. 28
Dimerix Bioscience Pty Ltd 29
GlaxoSmithKline Plc 30
Mallinckrodt Plc 31
Omeros Corporation 32
Pfizer Inc. 33
Pharmalink AB 34
Retrophin Inc. 35
Rigel Pharmaceuticals, Inc. 36
Shire Plc 37
Toray Industries, Inc. 38
Variant Pharmaceuticals, Inc. 39
Glomerulonephritis - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(irbesartan + propagermanium) - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
ACH-4471 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
AMY-101 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
AVX-002 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
belimumab - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
blisibimod - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
budesonide - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
corticotropin - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
CXA-10 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
eculizumab - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
fostamatinib disodium - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
losmapimod - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
OMS-721 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
PF-1355 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
rituximab - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
SHP-627 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
sparsentan - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
TM-5484 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
VAR-200 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Glomerulonephritis - Dormant Projects 111
Glomerulonephritis - Discontinued Products 113
Glomerulonephritis - Product Development Milestones 114
Featured News & Press Releases 114
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA 114
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome 115
Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis 115
Mar 04, 2016: Amyndas' lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy 116
Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease 116
Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis 117
Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan 117
Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin 118
Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin 118
Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon 119
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon 120
Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon 120
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon 121
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon 121
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 123
Disclaimer 124

List of Tables

Number of Products under Development for Glomerulonephritis, H2 2016 10
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Development by Companies, H2 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Glomerulonephritis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016 22
Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 23
Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 24
Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H2 2016 25
Glomerulonephritis - Pipeline by Avexxin AS, H2 2016 26
Glomerulonephritis - Pipeline by Biogen Inc, H2 2016 27
Glomerulonephritis - Pipeline by Complexa, Inc., H2 2016 28
Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 29
Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2016 30
Glomerulonephritis - Pipeline by Mallinckrodt Plc, H2 2016 31
Glomerulonephritis - Pipeline by Omeros Corporation, H2 2016 32
Glomerulonephritis - Pipeline by Pfizer Inc., H2 2016 33
Glomerulonephritis - Pipeline by Pharmalink AB, H2 2016 34
Glomerulonephritis - Pipeline by Retrophin Inc., H2 2016 35
Glomerulonephritis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 36
Glomerulonephritis - Pipeline by Shire Plc, H2 2016 37
Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2016 38
Glomerulonephritis - Pipeline by Variant Pharmaceuticals, Inc., H2 2016 39
Assessment by Monotherapy Products, H2 2016 40
Assessment by Combination Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Glomerulonephritis - Dormant Projects, H2 2016 111
Glomerulonephritis - Dormant Projects (Contd..1), H2 2016 112
Glomerulonephritis - Discontinued Products, H2 2016 113

List of Figures

Number of Products under Development for Glomerulonephritis, H2 2016 10
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 40
Number of Products by Top 10 Targets, H2 2016 42
Number of Products by Stage and Top 10 Targets, H2 2016 42
Number of Products by Top 10 Mechanism of Actions, H2 2016 44
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 44
Number of Products by Routes of Administration, H2 2016 46
Number of Products by Stage and Routes of Administration, H2 2016 46
Number of Products by Molecule Types, H2 2016 48
Number of Products by Stage and Molecule Types, H2 2016 48
  • Hyperoxaluria - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 44
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperoxaluria - Pipeline Review, H2 2016, provides an overview of the Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.Hyperoxaluria is defined by the presence of excess amounts of oxalic acid (oxalate) in the urine. Symptoms include severe or sudden abdominal or flank pain, blood in the urine, fever and chills, loss of appetite, nausea and vomiting. Treatment includes a low-oxalate di......
  • Global Urinary Incontinence Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 08-Nov-2016        Price: US 3480 Onwards        Pages: 111
    Urinary incontinence products, such as pads, are not a cure for urinary incontinence; however, using these pads and other devices to contain urine loss and maintain skin integrity are extremely useful in selected cases. Absorbent products used include underpads, pant liners (shields and guards), adult diapers (briefs), a variety of washable pants, and disposable pad systems, or combinations of these products. Scope of the Report: This report focuses on the Urinary Incontine......
  • Toviaz -Drug Insights, 2016
    Published: 01-Nov-2016        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Toviaz- Drug Insights, 2016" highlights the Toviaz marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Toviaz covering the total sales estimation and also provides the Toviaz sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Toviaz, patents information and exclusivity......
  • Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Dysuria Report is to understand the market and pipeline status of the drugs around the Dysuria to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline start......
  • Interstitial Cystitis  - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Interstitial Cystitis - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Interstitial Cystitis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, t......
  • Fistula-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Fistula-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Fistula. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, pat......
  • Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast-2023
    Published: 01-Nov-2016        Price: US 4950 Onwards        Pages: 100
    DelveInsight's Nocturnal Enuresis - Market Insights, Epidemiology and Market Forecast-2023" Reports provides an overview of the disease and global market trends of the Crohn's disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Nocturnal Enuresis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the re......
  • Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Interstitial Cystitis (Painful Bladder Syndrome)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Interstitial Cystitis (Painful Bladder Syndrome) Report is to understand the market and pipeline status of the drugs around the Interstitial Cystitis (Painful Bladder Syndrome) to explore t......
  • Urinary Incontinence  - Epidemiology Forecast To 2023
    Published: 01-Nov-2016        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Urinary Incontinence - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Urinary Incontinence in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Urinary Incontinence prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs